Molecular therapy for glioblastoma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Therapy

Background:

• Glioblastoma (GB) is the most common and malignant primary brain tumor, with a poor prognosis of 1-2 years despite conventional treatments.
• Molecular therapies represent a promising avenue for effective and potentially curative treatment of glioblastoma.

Purpose of the Study:

• To review and discuss various molecular strategies for glioblastoma treatment.
• To highlight key considerations for developing optimal molecular therapies, including gene vectors, administration routes, and preclinical studies.

Main Methods:

• Review of existing molecular strategies tested in animal models and clinical trials.
• Discussion of gene vectors (adenovirus, retrovirus, herpes simplex virus) and administration routes (intratumoral, intracarotid).
• Emphasis on minimizing collateral damage and the importance of preclinical validation.

Main Results:

• Several molecular strategies show potential, including prodrug systems, gene therapy, growth factor inhibition, anti-angiogenesis, immunotherapy, oncolytic viruses, and MMP inhibitors.
• Optimal molecular therapy requires careful selection of gene vectors and administration routes to maximize efficacy and minimize toxicity.
• Combinatorial approaches involving multiple simultaneous therapeutic modalities are likely the future of glioblastoma treatment.

Conclusions:

• Molecular therapy holds significant promise for treating glioblastoma.
• Careful consideration of gene vectors, delivery methods, and minimizing off-target effects are crucial for successful clinical translation.
• Rigorous, controlled therapeutic trials are essential to evaluate the safety and efficacy of these advanced glioblastoma treatments.